Table 3 Comparison of LORA and YORA patients
Variable | LORA (n = 69) | EORA (n = 181) | p-value |
|---|---|---|---|
Age (mean) | 68.93 ± 6.5 | 49.93 ± 9.68 |  |
Gender (female/male) | 47/22 | 141/40 | 0.201 |
Seropositivity (n/%) | 43 (62.3%) | 151 (83.4%) | 0.000* |
Symptom duration (mean/years) | 2.59 ± 3.06 | 3.48 ± 5.17 | 0.404 |
Large joint involvement (n/%) | 40 (58%) | 87 (48.1%) | 0.104 |
Only large joint involvement (n/%) | 6 (8.7%) | 14 (7.7%) | 0.491 |
Erosive disease (n/%) | 20 (29%) | 44 (24.3%) | 0.273 |
Extraarticular manifestations (n/%) | 5 (7.2%) | 7 (3.9%) | 0.211 |
CRP (mean/mg/L) | 31.9 ± 28.24 | 22.56 ± 31.6 | 0.000* |
DAS 28 (mean) | 4.8 ± 0.69 | 4.58 ± 0.65 | 0.024* |
SDAI (mean) | 12.5 ± 5.97 | 14.37 ± 4.4 | 0.066 |
CDAI (mean) | 14.89 ± 5.42 | 11.01 ± 5.56 | 0.443 |
Remission (n/%) | 30 (43%) | 56 (30%) | 0.044* |
LDA (n/%) | 28 (40%) | 85 (44%) | 0.223 |
MTX nonresponders (n/%) | 8 (11.6%) | 18 (9.9%) | 0.246 |
MTX withdrawal due to adverse events (n/%) | 7 (10.1%) | 29 (16%) | 0.163 |
MTX withdrawal due to nausea-vomiting (n/%) | 3 (4%) | 23 (12%) | 0.038* |